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Gabaculine, 5-amino-l,3-cyclohexadienylcarboxylate, is an analogue of GABA and a potent irreversible inhibitor of GABA aminotransferase. 
However, D-3-aminoisobutyrate-pyruvate minotransferase for which GABA was neither a substrate nor an inhibitor was also inactivated by 
gabaculine. The KS for D-3-aminoisobutyrate-py~vate aminotransferase was 8.3 x lob6 M, and the L8 fot its turnover was 0.31 mini at 25°C. 
B-Alanine protected the enzyme from inactivation by gabaculine, but GABA did so to much a lesser extent. 
Gabaculine; D-3-Aminoisobutyrate-pyruvate minotransferase; GABA aminotransferase; fi-Alanine; y-Aminobutyric acid 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Gabaculine is a naturally occurring neurotoxin 
isolated from Streptomyces toyocaensis [ 11. It is an ir- 
reversible inhibitor of pyridoxal phosphate linked w- 
amino acid ~inotransferases such as amino butyrate 
aminotransferase (/3-alanine-oxoglutarate aminotrans- 
ferase, &AlaAT I; EC 2.6.1.19) [2-71, /3-alaninepy- 
ruvate aminotransferase (EC 2.6.1.18) [IB] and ornithi- 
neoxo-acid aminotransferase [9, IO]. More recent 
studies have shown that gabaculine inhibited L-alanine 
aminotransfer~e [ 11,121, L-aspartate aminotr~sfer- 
ase {12] and D-amino acid aminotransferase 1131 with a 
correlation with the enzymic exchange of &protons 
from their normal substrate [12]. The Ki for the inac- 
tivation of w-amino acid aminotransferase by 
gabaculine had a much lower value than those of CY- 
amino acid transferase [12f. 
Recently, we purified @-AlaAT I [ 141 and R-3-amino- 
isobutyrate-pyruvate aminotransferase ((R)-3-amino- 
2-methylpropionate-pyruvate aminotransferase, @- 
AlaAT II; EC 2.6.1.40) [15] from rat liver. @-Alanine is 
a common amino donor to both enzymes, and Camino- 
butyrate is not broken down by @-AlaAT II. We found 
that gabaculine also acted as a potent irreversible in- 
hibitor of P-AlaAT II. 
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Abbreviations: GABA, 4-aminobutyrate; @AlaAT I, GABA 
aminotransferase; @AlaAT II, D-3-aminoisobutyrate-pyruvate 
am~notransferase 
All reagents were of analytical grade and were purchased from 
Nacalai Tesque (Kyoto) unless otherwise stated. DL-Gabaculine was 
obtained from Calbiochem-Behring Corp. &[2-%]Alanine was pur- 
chased from New England Nuclear. 
@-AlaAT II was purified from rat liver by heat treatment, ammo- 
nium sulfate fractionation and preparative chromatography using 
DEAE-Sepharose CL-6B, hydroxyapatite, Sephacryl S-200 and 
chromatofocusing [15]. Purified /3-AlaAT I from rat liver was 
prepared as previously reported [14]. The both enzymes were shown 
to be homogeneous by polyacrylamide gel electrophoresis n both the 
presence and absence of SDS. The specific activities of @-AlaAT I and 
@Ah&T II were 0.41 and 0.33 ~moI,min-‘.mg-i, respectivefy, 
under standard assay conditions. 
2.1. Inactivation kinetics 
Enzyme was incubated with gabaculine in 40 mM potassium 
pyrophosphate, pH 8.5, at 25°C. Aliquots were removed periodically 
and diluted at least I:40 with the assay mixture. The data were plotted 
as a semilog function of time. The slope of this plot gave the pseudo- 
first-order rate constant for inactivation, 
2.2. Enzyme assay 
The activities of @-AlaAT I and fl-AlaAT II were determined by the 
amount of malonate semialdehyde produced from @-alanine using 
2oxoglutarate and pyruvate, respectively, according to the methods 
previously described [14,15]. The standard reaction mixture contain- 
ed 50 mM trjethanol~ine, pH 7.3, 5 mM 2-mercaptoethanol, 0.5 
mM pfyridoxal 5 ‘-phosphate, 1 mM /3-[2-i4C]alanine (spec. act. 37 
GBq/mol) and 1 mM 2-oxoglutarate or 1 mM pyruvate in a final 
volume of 1 .O ml. The incubation was carried out in a shaking water 
bath for 10 min at 37’C. The reaction was terminated by the addition 
of 0.5 ml 2 M HCl and the tube was immediately transferred to an ice 
bath. After adding 0.02 ml of 1 M @alanine and 0.2% 2,4-dinitro- 
phenylhydrazine (in 2 M HCl), the mixture was allowed to stand at 
37°C for 15 min and the dinitrophenylhydrazone formed was ex- 
tracted by shaking with 5.0 ml toluene. After brief centrifugation, the 
radioactivity of a 2-ml aliquot of the extract was measured with a 
Packard Tri-Carb liquid scintillation spectrometer (460 CD type). 
One unit of @AlaAT I and @-AlaAT II was defined as the amount of 
enzyme which catalyzed the formation of 1.0 pmol malonate 
semi~dehyde/min under the given conditions. 
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Fig. 1. Irreversible inhibition of @-AlaAT I from rat liver by gabaculine and the effects of substrates on its kinetics. (A) Concentration dependence 
of the inactivation of P-AlaAT 1 by DL-gabaculine. fl-AlaAT I (44 pg = 18 mu) was incubated in 40 mM potassium pyrophosphate, pH 8.5, with 
the indicated concentrations of gabaculine at 25OC, and the inactivation rate constant was calculated as described in section 2. The data are 
presented as a double-reciprocal plot of inactivation rate constant versus concentration of gabaculine. (B) Effect of substrates on the rate of inac- 
tivation. fl-AlaAT I (44 pg = 18 mu) was incubated in 40 mM potassium phosphate buffer, pH 8.5, at 25°C in a total volume of 300 ~1 by itself 
(0) or with final concentrations of the following: (e) 5 pM DL-gabaculine; (0) 5 pM DL-gabaculine and 10 mM 2-oxoglutarate; (D) 5 pM DL- 
gabaculine and 10 mM p-alanine; (A) 5 CM DL-gabaculine and 5 mM GABA; (A) 5 pM DL-gabaculine and 10 mM GABA. At the indicated times, 
aliquots were removed and assayed for residual activity as described in section 2. The data are presented as semilog plots of the percentage of initial 
activity versus time. 
3. RESULTS AND DISCUSSION 
When gabaculine is transaminated by partially 
purified &Ah&T I from Pseudomonas ffuorescens, it 
is converted to a stable m-anthranilic acid derivative 
(m-carboxyphenylpryridoxamine phosphate) [5]. This 
adduct binds tightly to the active site of the enzyme and 
can be liberated under denaturing conditions [5]. 
Gabaculine acts also as a competitive inhibitor of +!3- 
AlaAT I from both brain and Pseudomonas ovalis [3]. 
Purified /3-alanine-pyruvate aminotransferase from 
Pseudomonas species F-126 catalyzes the transfer of 
amino groups of various w-amino acids containing 
GABA [16] and gabaculine inactivated the enzyme ac- 
tivity with a Ki value of 2.02 mM [S]. 
When purified PAlaAT I from rat liver was incubated 
O-Alanine (mM) 
Fig. 2. @-AlaAT II activity as a function of p-alanine in the presence 
or absence of GABA. (0) control, (0) 5 mM GABA. Other condi- 
tions were the same as for the standard assay. 
with gabaculine, a rigid analogue of GABA, the enzyme 
was inactivated with a pseudo-first-order profile 
{Fig. 1A) with an apparent Ki of 7.1 PM; maximum rate 
of inactivation, 0.40 min- ‘; half-life, 1.7 min 
(Fig. 1B). P-Alanine as well as GABA afforded 
substantial protection, although 2-oxoglutarate was not 
effective (Fig. 1A). 
In a previous paper [lS], we described that GABA is 
a poor substrate of P-Ah&T II. As shown in Fig. 2, the 
addition of 5 mM GABA did not decrease the initial 
reaction velocity of ,&AlaAT II at various @-alanine 
concentrations. However, incubation of fl-AlaAT II 
with gabaculine at various concentrations led to the in- 
hibition of the enzyme (Fig. 3). Aliquots were removed 
periodically and assayed for residual enzyme activity. 
The control did not lose activity for up to approximate- 
ly 1 h under the experimental conditions. Inactivation 
followed pseudo-first-order kinetics to complete loss of 
activity and the inhibited enzyme was not reactivated by 
continued dialysis against 0.1 M potassium phosphate, 
pH 7.5, containing 1 mM EDTA, 2 mM 
2-mercaptoethanol and 40 FM pyridoxal 5 ’ -phosphate 
overnight at 5°C. @AlaAT II is saturable with 
gabaculine. The kinetic data calculated from Fig. 3A 
are as follows: apparent KS, 8.3 FM; maximum rate of 
inactivation, 0.31 min- r; half-life, 2.2 min. The Ki 
value was 240 times smaller than that of the Ki found by 
Burnett et al. [S] for Pseudomonas /3-alanine-pyruvate 
aminotransferase. From these results, gabaculine acts 
as a potent inhibitor of p-AlaAT II rather like its effects 
on @AlaAT I. 
Substrates for @-AlaAT II from rat liver have a mark- 
116 
Volume 276, number 1,2 FEBS LETTERS December 1990 
1 2 
1 /Gabaculine (NM-’ ) 
B 
~ 100 
C .- 
c 
.- 
g 50 
L 
% 
> .- 
3 
Z 
al 
: 
a 
10 
0 10 20 30 
Time (min) 
Fig. 3. Inhibition of P-AlaAT II from rat liver by gabaculine and the effects of substrates on its kinetics. (A) Concentration dependence of the 
inactivation of fi-AlaAT II by DL-gabaculine. @-AlaAT II (5.5 pg = 1.8 mu) was incubated in 40 mM potassium pyrophosphate, pH 8.5, with 
the indicated concentrations of gabaculine at 25”C, and the inactivation rate constant was calculated as described in section 2. The data are 
presented as a double-reciprocal plot of inactivation rate constant versus concentration of gabaculine. (B) Effect of substrates on the rate of inac- 
tivation. &AlaAT II (5.5 pg = 1.8 mu) was incubated as described in Fig. 2: (0) control; (0) 5 pM DL-gabaculine; (0) 5 PM DL-gabaculine and 
IO mM pyruvate; (n ) 5 mM DL-gababuline and 1 mM /3-alanine; (A) 5 pM DL-gabaculine and 5 mM GABA; (A) 5 pM DL-gabaculine and 10 
mM GABA. 
ed effect on the rate of inactivation (Fig. 3B). /3- 
Alanine itself strongly retards the rate of inactivation, 
while GABA shows weaker effects and pyruvate has a 
moderate protective effect. Non-substrate 2-oxo-acids, 
such as 2-oxoglutarate, did not protect against inactiva- 
tion by gabaculine (not shown). These experiments ug- 
gest that gabaculine preferentially interacts with the 
pyridoxal phosphate form of the coenzyme and does 
not affect the pyridoxamine phosphate form. Ornithine 
aminotransferase for Bacillus sphaericus IF0 3525 did 
not utilize GABA as a substrate [171 but was irreversibly 
inactivated by gabaculine [lo]. However, the activity of 
ornithine aminotransferase from animals was inhibited 
by GABA [ 18-201. On the other hand, although GABA 
did not act as a substrate or inhibitor or purified p- 
AlaAT II from rat liver, gabaculine acted as a potent ir- 
reversible inhibitor. If judged by the Ki and &at values, 
/3-AlaAT II as well as @AlaAT I are alternatively sen- 
sitive to gabaculine. As @alanine and pyruvate prevent 
the inactivation of @-AlaAT II (Fig. 3B), the presence 
of substrates may inhibit binding between gabaculine 
and pyridoxal phosphate at the active site. 
The K,,, values for /3-alanine with purified rat liver p- 
AlaAT I and &Ah&T II were 6.3 mM [14] and 0.81 
mM [ 151, respectively. We found the Ki values for 
gabaculine with rat liver P-AlaAT I and /3-AlaAT II to 
be 7.1 PM and 8.3 PM, respectively. The Ki values for 
gabaculine with L-alanine transaminase and L- 
aspartate transaminase were 1 mM and 55 mM, respec- 
tively [13], and these values were much higher than 
those of the above w-amino acid aminotransferase. 
Gabaculine commonly inhibits o-amino acid 
aminotransferases uch as /3-AlaAT I, @AlaAT II, fl- 
alanine-pyruvate aminotransferase, and ornithine 
aminotransferase and it is very sensitive. The binding of 
gabaculine to the enzymes may lead to an irreversible 
change in the active site. Therefore, gabaculine may be 
a useful tool to study the geometry and catalytic func- 
tion of o-amino acid aminotransferases. 
P-Alanine formed by the degradation of uracil, is 
widely distributed in brain [21]. (R)-&Aminoisobuty- 
rate is an end product of the metabolic degradation of 
thymine. Thus, gabaculine may facilitate the study of 
the function of &aminoisobutyrate as well as ,&alanine 
including &AlaAT II on the nervous system. 
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